Protecting Consumer Privacy in DTC Tissue Testing
The privatization of next-generation medical technologies, especially in regenerative and precision medicine, further muddies the data-protection waters.
precision medicine
-
Read more: Protecting Consumer Privacy in DTC Tissue Testing -
Read more: Why We Should Care About the Move from Saliva to Living Cells in Precision Medicine Why We Should Care About the Move from Saliva to Living Cells in Precision Medicine
Could a corporate, direct-to-consumer cell-based testing service be the next 23andme? And what would that mean for patients?
-
Read more: European Skew in Genetic Research Databases Won’t Abate Without More Concerted Effort European Skew in Genetic Research Databases Won’t Abate Without More Concerted Effort
Continued efforts to increase diversity in genetic research are needed.
-
Read more: The Journal of Law and the Biosciences’ Growing Impact The Journal of Law and the Biosciences’ Growing Impact
The Journal of Law and the Biosciences ranks first in the legal medicine category, second in medical ethics, and third among ethics journals.
-
Read more: Transplant Genomics: Ethical, Legal, and Social Implications Transplant Genomics: Ethical, Legal, and Social Implications
Advances in genetic and genomic studies have identified an increasing number of novel biomarkers of potential use in transplant-related care.
-
Read more: Assessing genetic relationships between academia and industry Assessing genetic relationships between academia and industry
By Kayte Spector-Bagdady With recent reports of Google’s data deals with Ascension health and the University of Chicago, there has been a lot of attention paid recently to the sharing and use of health data by unexpected entities. But we know that patients are uncomfortable when hospitals “commercialize” or sell their health data or biospecimens…
-
Read more: Rethinking Inclusivity in Precision Medicine Research: The Disability Experience and Barriers to Participation Rethinking Inclusivity in Precision Medicine Research: The Disability Experience and Barriers to Participation
Persons with disabilities constitute the largest health disparities group in the U.S., but they have largely been absent from the conversations on precision medicine research.
-
Read more: What’s in a name? Why metaphors matter for genetics research What’s in a name? Why metaphors matter for genetics research
By Mildred K. Cho, PhD In 2017, the US FDA approved a gene therapy for the first time. However, it’s important to remember that the term “gene therapy” has been an optimistic misnomer for nearly 30 years, since the first clinical trial of a gene-based intervention was initiated in 1990. Although the FDA has now…
-
Read more: The Precision Medicine Initiative and Access The Precision Medicine Initiative and Access
By Leslie Francis Persistent differences in participation in clinical trials by race and ethnicity are well known; for example, the 2015 Report of the Working Group on Precision Medicine (PMI) relies on statistics that only 5% of clinical trial participants are African-American and only 1% are Hispanic. A recently-launched website of the FDA, “Drug Trials…